Immunome Reports Third Quarter 2023 Financial Results

– Completed merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors

– Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO

– Bob Lechleider, M.D., appointed as Chief Medical Officer

– Jean-Jacques Bienaimé, former CEO of BioMarin appointed as member of the Board of Directors

– Cash runway expected to extend into Q1 2026*

See more here